{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-064415","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.969936+00:00","generated_at":"2026-05-22T13:38:29.373472+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioAtla Q1 net loss $15.3M; cash $32.4M; Mec-V shows 59% 2-year OS in mKRAS NSCLC","bullets":["Net loss $15.3M vs $23.2M YoY; R&D expenses down to $12.4M from $18.9M.","Cash $32.4M at March 31, 2025; expects runway beyond key readouts in 1H 2026.","BA3182 Phase 1 dose-escalation ongoing; data readout mid-2025; three patients dosed at 300 µg.","Mec-V in mKRAS NSCLC shows 67% 1-year and 59% 2-year landmark OS (SOC <20%).","Oz-V in HPV+ SCCHN: 45% ORR (5/11), 100% disease control; Fast Track discussions with FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-064415","json":"https://secwatch.observer/filing/0000950170-25-064415.json","markdown":"https://secwatch.observer/filing/0000950170-25-064415.md","text":"https://secwatch.observer/filing/0000950170-25-064415.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000095017025064415/0000950170-25-064415-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000095017025064415/bcab-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T13:38:29.373472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}